RNS Number:1754T
Bespak PLC
12 December 2003


For immediate release                                           12 December 2003



                                   Bespak plc


                               Analyst Site Visit



Bespak (LSE: BPK), the drug delivery company, announces that it is holding a
site visit today for analysts at its newly extended King's Lynn facility in
Norfolk.



The visit will involve a tour of the site, as well as presentations from senior
management on key areas of the business including Device & Manufacturing
Services, Respiratory Drug Delivery and Operations.  The visit will provide
analysts with an update on the Company's growth strategy together with an
opportunity to gain an in-depth awareness and understanding of Bespak's
business.



No material new financial information will be disclosed today.  The Group plans
to announce its Preliminary results on 20 January 2004.



For further information please call:


Bespak plc                                              Tel:  +44(0)1908 552600

Mark Throdahl, CEO

Buchanan Communications                                 Tel:  +44(0)20 7466 5000

Tim Thompson, Mark Court, Mary-Jane Johnson



Notes to editors



About Bespak plc

Bespak is in the forefront of developing new delivery systems for the
pharmaceutical industry. The company has a product range covering metered dose
inhalers, dry powder devices, actuators and compliance aids. The company also
develops and manufactures drug delivery devices for leading global
pharmaceutical companies such as the DiskusTM dry powder inhaler, the drug
delivery device used in GlaxoSmithKline's blockbuster asthma treatment Advair/
Seretide. The group has facilities in King's Lynn and Milton Keynes in the UK
and in Cary, North Carolina, in the USA. Bespak is a public company quoted on
the Official list of the London Stock Exchange (LSE: BPK).  For more information
go to www.bespak.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCGUGCAPUPWGQG